Skip to content

The Joint Corp. JYNT Stock option exercise receivable

Stock option exercise receivable at other companies

Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$3K-80.0%
Ondas, Inc.
 logo
Ondas, Inc. ONDS
$2.97M
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$304K
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$60.25K
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$40K
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE
$88K

Other financials

Income statement

See full
Revenue$14.8M+13.3%
Gross profit$12.1M+19.7%
Operating income$873.7K+229%
Net income$1.3M+34.2%
EPS (diluted)$0.09+50.0%

Balance sheet

See full
Cash & equivalents$21.4M-6.4%
Total debt$2.0M-9.3%
Total equity$15.5M-22.3%
Total assets$57.9M-25.0%

Cash flow

See full
Operating cash flow-$1.5M+60.1%
CapEx$234.6K-29.2%
Free cash flow-$1.7M+57.6%

Valuation

See full
Market cap$127.87M-28.0%
Enterprise value$108.49M-27.1%
P/E39.5×
P/S2.3×-0.2×

Profitability

See full
Gross margin80.6%-6.0pp
Operating margin1.1%+0.7pp
Net margin5.7%+3.7pp
FCF margin7.2%-0.4pp

Returns & leverage

See full
Return on equity18.3%+11.6pp
Debt / equity0.1×0.0×
Current ratio1.6×+0.1×

Where this comes from

Reported directly by The Joint Corp. in its filing.

Tagged under the XBRL concept jynt:StockOptionExerciseReceivable.

The official record: The Joint Corp.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Joint Corp.'s stock option exercise receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Joint Corp.'s stock option exercise receivable?
The Joint Corp. (JYNT) reported stock option exercise receivable of $0 in Q4 2025.
How has The Joint Corp.'s stock option exercise receivable changed year-over-year?
The Joint Corp.'s stock option exercise receivable decreased by 100.0% year-over-year, from $224.19K to $0.
What does stock option exercise receivable mean?
This metric represents the amount owed to the company by employees or directors who have exercised stock options but have not yet settled the payment. It highlights a temporary gap between the issuance of equity and the receipt of cash proceeds. Tracking this provides insight into the efficiency of the company's equity compensation administration and short-term cash conversion.